businessFeb 27, 202533:15pending
Atai: Following the path that Spravato laid and moving beyond it
About this episode
Pursuing social anxiety disorder with MDMA. Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds (1:30). Standing on the shoulders of Johnson & Johnson's Spravato (4:00). Upcoming milestones and clinical trials (13:15). Psychedelic industry sentiment; RFK Jr influence (30:40).
Show Notes:
Psychedelic Stocks: Focus On Their Cash
Deep Dive: Atai Life Sciences
FDA's MDMA Decision A Setback, But Long-Term Outlook For Psychedelic Stocks Unchanged
Read our episode transcripts
For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions
Show Notes:
Psychedelic Stocks: Focus On Their Cash
Deep Dive: Atai Life Sciences
FDA's MDMA Decision A Setback, But Long-Term Outlook For Psychedelic Stocks Unchanged
Read our episode transcripts
For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions
Get every episode summarized
Each time Investing Experts publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Investing Experts
Momentum, fear & the case for buying the dip
Investing Experts
Sep 3, 202628:56failed
Tax Loss Harvesting: Tax Alpha with Raul Shah
Investing Experts
Sep 2, 202624:02pending
Don't sleep on software
Investing Experts
Aug 25, 202643:04pending
Hedging exposure in this volatile market
Investing Experts
Aug 20, 202635:28pending